Harel Insurance Investments & Financial Services Ltd. lifted its stake in shares of Cencora, Inc. (NYSE:COR - Free Report) by 44.7% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 24,468 shares of the company's stock after buying an additional 7,557 shares during the quarter. Harel Insurance Investments & Financial Services Ltd.'s holdings in Cencora were worth $8,264,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other large investors also recently modified their holdings of the company. Vanguard Group Inc. lifted its holdings in shares of Cencora by 0.9% in the 4th quarter. Vanguard Group Inc. now owns 23,617,117 shares of the company's stock worth $7,976,681,000 after purchasing an additional 221,570 shares in the last quarter. State Street Corp lifted its holdings in shares of Cencora by 9.3% in the 3rd quarter. State Street Corp now owns 9,190,316 shares of the company's stock worth $2,872,249,000 after purchasing an additional 782,911 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Cencora by 21.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 4,677,797 shares of the company's stock worth $1,461,965,000 after purchasing an additional 821,098 shares in the last quarter. Boston Partners lifted its holdings in shares of Cencora by 2.0% in the 3rd quarter. Boston Partners now owns 4,509,165 shares of the company's stock worth $1,409,152,000 after purchasing an additional 89,506 shares in the last quarter. Finally, Wellington Management Group LLP lifted its holdings in shares of Cencora by 3.0% in the 3rd quarter. Wellington Management Group LLP now owns 3,971,121 shares of the company's stock worth $1,241,094,000 after purchasing an additional 115,278 shares in the last quarter. 97.52% of the stock is currently owned by institutional investors.
Cencora Trading Up 0.7%
Shares of COR opened at $305.89 on Wednesday. The business has a 50-day moving average of $332.27 and a 200 day moving average of $343.21. Cencora, Inc. has a fifty-two week low of $271.00 and a fifty-two week high of $377.54. The firm has a market cap of $59.50 billion, a P/E ratio of 36.77, a price-to-earnings-growth ratio of 1.42 and a beta of 0.64. The company has a debt-to-equity ratio of 3.62, a quick ratio of 0.51 and a current ratio of 0.92.
Cencora (NYSE:COR - Get Free Report) last announced its quarterly earnings data on Wednesday, February 4th. The company reported $4.08 earnings per share for the quarter, topping the consensus estimate of $4.04 by $0.04. Cencora had a return on equity of 176.54% and a net margin of 0.50%.The company had revenue of $85.93 billion during the quarter, compared to analyst estimates of $86.12 billion. During the same quarter last year, the firm posted $3.73 EPS. The firm's revenue for the quarter was up 5.5% on a year-over-year basis. As a group, research analysts forecast that Cencora, Inc. will post 17.58 EPS for the current year.
Wall Street Analysts Forecast Growth
Several equities analysts have weighed in on the company. Leerink Partners restated an "outperform" rating on shares of Cencora in a research note on Tuesday, March 17th. JPMorgan Chase & Co. raised their price objective on Cencora from $417.00 to $419.00 and gave the company an "overweight" rating in a research note on Tuesday, February 10th. Wells Fargo & Company raised their price objective on Cencora from $405.00 to $429.00 and gave the company an "overweight" rating in a research note on Tuesday, February 10th. William Blair assumed coverage on Cencora in a research note on Tuesday, April 28th. They set a "market perform" rating on the stock. Finally, Evercore set a $360.00 price objective on Cencora in a research note on Wednesday, April 8th. Twelve analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $398.17.
View Our Latest Analysis on Cencora
About Cencora
(
Free Report)
Cencora NYSE: COR is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company's core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.
Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.
Further Reading
Want to see what other hedge funds are holding COR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cencora, Inc. (NYSE:COR - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Cencora, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cencora wasn't on the list.
While Cencora currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
